Phyton Biotech Wins Grant to Develop New Approaches to Manufacturing Artemisinin

December 4, 2017
Phyton Biotech

Bill & Melinda Gates Foundation Invests in R&D Pilot for Anti-Malarial Active Pharmaceutical Ingredients AHRENSBURG, Germany, November 29, 2017 – Phyton Biotech today announced that it has received a $400,000 grant from the Bill & Melinda Gates Foundation to fund the research and development of an alternative method of producing artemisinin, a key active pharmaceutical … Continue reading Phyton Biotech Wins Grant to Develop New Approaches to Manufacturing Artemisinin

Aequus Provides Third Quarter 2017 Operational Highlights

November 29, 2017
Aequus Pharmaceuticals Inc.

VANCOUVER, November 29, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended September 30, 2017 and associated Company developments. Unless otherwise noted, all figures are in Canadian currency. … Continue reading Aequus Provides Third Quarter 2017 Operational Highlights

Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer

Qu Biologics Inc.

Vancouver, British Columbia – November 28th, 2017 Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has just published collaborative research with Dartmouth College detailing the mechanism of action and efficacy of Qu’s lung-targeted SSI, QBKPN, for the treatment … Continue reading Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer

Arbutus Announces Presentations at HepDART 2017

November 27, 2017
Arbutus Biopharma Corporation

VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced two oral presentations and one poster presentation at HepDART 2017 being held on December 3 – 7, 2017 in Kona, Hawaii. Presentations Include: Oral Presentation: “Controlling HBsAg as a Key Component of a Combination Strategy to Affect … Continue reading Arbutus Announces Presentations at HepDART 2017

Aquinox to Participate in 29th Annual Piper Jaffray Healthcare Conference

November 23, 2017
Aquinox Pharmaceuticals, Inc.

VANCOUVER, British Columbia, Nov. 22, 2017 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will participate in a fireside chat presentation at the upcoming 29th Annual Piper Jaffray Healthcare Conference … Continue reading Aquinox to Participate in 29th Annual Piper Jaffray Healthcare Conference

DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting

November 21, 2017
DelMar Pharmaceuticals, Inc.

40% of recurrent GBM patients treated to date achieved stable disease as measured by magnetic resonance imaging (MRI) VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 21, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today provided an overview of … Continue reading DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting

LifeSciences BC Announces Appointment of Richard Osborn to Board of Directors

November 20, 2017
LifeSciences BC

Richard Osborn Vancouver, B.C. – November 16, 2017, Dr. Lesley Esford, President & CEO of LifeSciences BC, is pleased to announce that Richard Osborn has joined the LifeSciences BC Board of Directors.  Richard is the Managing Partner of TELUS Ventures, the strategic investment arm of TELUS Corporation. Before joining TELUS Ventures in 2016, Richard was … Continue reading LifeSciences BC Announces Appointment of Richard Osborn to Board of Directors

CDRD Appoints Dr. Rachael Ritchie Vice President, Strategy and Partnerships

November 16, 2017
The Centre for Drug Research and Development

Vancouver, Canada – November 16, 2017: The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization engine, is pleased to announce the appointment of Dr. Rachael Ritchie as Vice President, Strategy & Partnerships effective December 1, 2017. Dr. Ritchie brings to CDRD a background that spans the University of British Columbia, … Continue reading CDRD Appoints Dr. Rachael Ritchie Vice President, Strategy and Partnerships

Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole

Aequus Pharmaceuticals Inc.

VANCOUVER, BC. November 16th, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the European Patent Office has issued an intention to grant a European patent for AQS1301, Aequus’ once-weekly transdermal patch containing aripiprazole. … Continue reading Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole

Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran

Arbutus Biopharma Corporation

VANCOUVER, B.C. and WARMINSTER, Pa., Nov. 16, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company’s lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for … Continue reading Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran